|1.||Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis)
|2.||Takayasu Arteritis (Arteritis, Takayasu's)
|3.||Giant Cell Arteritis (Horton Disease)
|1.||Salvarani, Carlo: 24 articles (09/2015 - 11/2002)|
|2.||Boiardi, Luigi: 17 articles (09/2015 - 11/2002)|
|3.||Cid, Maria C: 17 articles (02/2015 - 05/2002)|
|4.||Pipitone, Nicolò: 15 articles (10/2014 - 04/2005)|
|5.||Hernández-Rodríguez, José: 13 articles (02/2015 - 05/2003)|
|6.||Weyand, Cornelia M: 13 articles (01/2011 - 01/2002)|
|7.||García-Martínez, Ana: 12 articles (02/2015 - 05/2003)|
|8.||Gonzalez-Gay, Miguel A: 12 articles (01/2010 - 09/2003)|
|9.||Prieto-González, Sergio: 11 articles (02/2015 - 06/2010)|
|10.||Goronzy, Jörg J: 11 articles (01/2011 - 01/2002)|
|1.||Adrenal Cortex Hormones (Corticosteroids)IBA
12/30/1982 - "Corticosteroids are still the best treatment of giant cell arteritis but the optimal initial dosage remains unknown as no data from randomized trials are available. "
08/01/2007 - "High-dose corticosteroids (CS) are the mainstay of treatment for temporal (giant cell) arteritis (TA). "
06/01/2003 - "To report the incidence and extent of visual deterioration in patients with giant cell arteritis (GCA) on high doses of systemic corticosteroids during the early stages of treatment; the various factors that may influence the outcome; and whether intravenous megadose corticosteroid therapy is more effective than oral therapy. "
09/01/2005 - "Corticosteroids remain the mainstay of treatment of giant cell arteritis. "
08/01/1999 - "Nevertheless, although the improvement in diagnostic yield of bilateral temporal artery biopsies is low, the consequences of both delayed diagnosis and treatment of giant cell arteritis as well as the use of systemic corticosteroids in patients who do not have giant cell arteritis are of such potential severity that consideration should always be given to performing bilateral temporal artery biopsies in patients suspected of having the disease."
|2.||Prednisone (Sone)FDA LinkGeneric
03/01/2015 - "To compare the effectiveness and safety of medium-dose (MD) and high-dose (HD) prednisone regimens and to identify factors related to remission with a target maintenance dose of prednisone in patients with giant cell arteritis (GCA). "
09/01/1993 - "We present here a review of the recent literature concerning temporal arteritis, followed by a report of an unusual case in which high-dosage prednisone therapy was effective in relieving the patient's symptoms and lowering the sedimentation rate in spite of a negative temporal artery biopsy."
11/01/1994 - "Due to the presumed diagnosis of giant cell arteritis (GCA), the patient was treated with prednisone (60 mg daily), with immediate improvement in his symptoms. "
05/01/2015 - "She was treated empirically for giant cell arteritis (GCA) with oral prednisone, which provided no symptom relief. "
03/01/2015 - "Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients."
05/01/2014 - "Tocilizumab, an effective treatment for relapsing giant cell arteritis."
01/01/2014 - "Tocilizumab is a promising treatment of giant cell arteritis but controlled trials are needed to confirm its efficacy."
01/01/2014 - "[Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review]."
05/01/2012 - "Efficacy of tocilizumab in refractory giant cell arteritis."
06/01/2015 - "Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients."
12/01/2012 - "Giant cell arteritis (GCA) has been successfully treated with steroids for many years and temporal artery biopsy (TAB) is regarded as the gold standard diagnostic test. "
02/01/2007 - "To establish the histological and immunohistochemical parameters that are helpful in recognising temporal arteritis in patients who have been treated with steroids before biopsy, and to analyse the clinical features and correlate them with the histological findings. "
04/01/1986 - "For some patients, the clinical diagnosis of temporal arteritis can be based on the clinical signs and symptoms and their response to a therapeutic trial of steroids."
06/16/2014 - "A presumptive diagnosis of giant cell arteritis was made and the patient was treated with high-dose steroids. "
02/01/2013 - "Steroids remain the treatment of choice for giant cell arteritis and must be instituted immediately upon suspicion of the diagnosis, even in the physician's office. "
|5.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
04/01/2012 - "Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study."
09/01/2010 - "Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels."
10/01/2000 - "Clues to the pathogenesis of giant cell arteritis from the study of the vessel wall."
03/01/2015 - "Large-vessel giant cell arteritis: a cohort study."
01/01/2015 - "Vessel wall enhancement of intradural arteries, mainly the ICA, can be regularly found in patients with giant cell arteritis. "
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/01/2005 - "However, randomized controlled trials are required to define the role of anti-tumor necrosis factor-alpha agents in the treatment of giant cell arteritis. "
05/01/2007 - "Tumor necrosis factor-alpha is present in arteries in giant cell arteritis. "
05/01/2008 - "Randomised controlled studies have so far not shown superiority of anti-TNF-alpha agents for Wegener's granulomatosis and giant cell arteritis. "
01/01/2006 - "We report a case of an elderly woman with giant cell arteritis (GCA) who developed Kaposi sarcoma while on a double blind trial for GCA with an anti-tumor-necrosis-factor medication. "
01/15/2008 - "Tumor necrosis factor blocking agents in polymyalgia rheumatica and giant cell arteritis."
01/01/2008 - "Glucocorticoids remain the mainstay of treatment of giant cell arteritis. "
05/01/2007 - "Differences between active treatment and placebo groups in the study of induction treatment of giant cell arteritis with high-dose glucocorticoids: comment on the article by Mazlumzadeh et al."
05/01/2014 - "Giant cell arteritis complicated by AION was suspected at the beginning and high-dose oral glucocorticoids were started. "
02/01/2014 - "To conduct a meta-analysis of published data of the effectiveness of drug treatment in giant cell arteritis (GCA) to provide evidence to support the optimal use of glucocorticoids (GCs) and adjunct therapy. "
01/01/2014 - "Glucocorticoids remain the mainstay of giant cell arteritis treatment. "
|8.||infliximab (Remicade)FDA Link
05/01/2007 - "This trial is too small to draw definitive conclusions, but it provides evidence that using infliximab as maintenance therapy in patients in glucocorticoid-induced remission of newly diagnosed giant cell arteritis is of no benefit and may be harmful. "
05/01/2007 - "Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial."
11/01/2007 - "Should infliximab be used to help maintain glucocorticosteroid-induced remission in patients with giant cell arteritis?"
05/01/2007 - "Adding infliximab to the treatment regimen for giant cell arteritis."
02/01/2006 - "Infliximab as monotherapy in giant cell arteritis."
11/01/1980 - "A controlled study of C-reactive protein in patients with and without temporal arteritis was performed. "
08/01/2014 - "The importance of the C-reactive protein test in evaluating the possibility of giant cell arteritis has recently been emphasized. "
09/01/2012 - "Giant cell arteritis with normal C-reactive protein and risk of ocular complications."
09/01/2012 - "Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein."
06/01/2012 - "To evaluate the utility of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for the diagnosis of giant cell arteritis (GCA) and to determine the frequency of normal ESR and CRP at diagnosis of GCA. "
|10.||Methotrexate (Mexate)FDA LinkGeneric
01/16/2001 - "Treatment with methotrexate plus corticosteroid is a safe alternative to corticosteroid therapy alone in patients with giant-cell arteritis and is more effective in controlling disease."
05/01/2002 - "A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis."
09/01/2001 - "With this study design, no corticosteroid-sparing benefit could be attributed to the combination of methotrexate with corticosteroid therapy for the treatment of patients with giant cell arteritis. "
09/01/2001 - "This was a randomized, controlled, double-blind trial comparing methotrexate versus placebo in addition to corticosteroid therapy in patients with newly diagnosed giant cell arteritis. "
09/01/2001 - "A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)."
|1.||Cardiopulmonary Resuscitation (CPR)
03/01/1991 - "A prospective clinical study of 23 patients with giant-cell arteritis (GCA) and/or polymyalgia rheumatica (PMR) was undertaken in order to assess the behaviour of the non-specific markers of the disease activity, the erythrocyte sedimentation rate (ESR) and other acute phase markers, particularly the C-reactive protein (CPR) and serum amyloid A apolipoprotein (apo SAA) levels during induction of disease remission by prednisone therapy, and possible further recurrence of GCA and/or PMR. "
05/01/1995 - "Reversible perfusion disorder on brain SPECT after treatment with prednisone in temporal arteritis."
08/01/1994 - "To investigate T cell receptor (TCR) V alpha/V beta (and in selected cases, J beta) usage in CD4+ and CD8+ peripheral blood lymphocytes of patients with giant cell arteritis (GCA), before and after treatment, as well as to analyze the HLA types of these patients. "
02/01/1992 - "Ninety-six patients with giant cell arteritis (GCA) seen from 1968 to 1985 were studied with regard to the starting dose of prednisolone and the development of serious ocular complications, which proved to be very few after treatment was started. "
01/01/1990 - "Basic hemorheological parameters like packed cell volume (PCV), plasma viscosity, red cell aggregation, red cell filterability and whole blood viscosity were measured in 18 patients (14 women, aged 75.4 years) with giant cell arteritis before and after treatment with steroids. "
01/01/1990 - "[Hemorheologic parameters in patients with giant cell arteritis before and after treatment with steroids]."
06/01/2002 - "CURRENT KNOWLEDGE ANS KEY POINTS: In polymyalgia rheumatica (PMR) unassociated with giant cell arteritis (GCA) (twice as frequent as GCA without PMR) several recent works demonstrated by MRI or echography that synovitis and/or subacromial bursitis accounted for most of the painful shoulders and could be relieved by steroid injections. "
10/01/1966 - "Restoration of vision in temporal arteritis by retrobulbar injections of steroids."
10/01/1986 - "Extensive giant cell arteritis of the small to medium-sized arteries was found unexpectedly in the ovaries and fallopian tubes of two patients who had prior hysterectomies and in the ovaries, fallopian tubes, and uterus of one patient. "
04/01/2005 - "Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed and subsequently revealed giant cell arteritis involving numerous small arteries in the ovaries, fallopian tubes, paraovarian and paratubal soft tissues, myometrium, and cervix. "
11/01/1990 - "Giant-cell arteritis involving the uterus was identified incidentally upon hysterectomy and anterior colporrhaphy for uterine prolapse. "
02/01/1979 - "In a patient who had a hysterectomy and bilateral salpingo-oophorectomy for endometrial adenocarcinoma, a giant cell arteritis was found in many of the myometrial and tubal vessels and in a few of the small arteries of the cervix and ovaries. "
06/01/2006 - "We present a very unusual clinical case of giant cell arteritis with uterus involvement, in a women of 66 years old, that began clinical features of pain and functional limitation of shoulders and hip 3 mouth before been operated of uterus prolapse with hysterectomy. "